Page 271 - fourth year book
P. 271

DIABETES MELLITUS



                      hyperglycemia  and  ketosis; therefore  vigorous  activity  should  be
                      avoided in the presence of ketosis.

                     Hypoglycemia:  in  individual  taking  insulin  and/or  insulin
                      secratagogues,  physical  activity  can  cause  hypoglycemia  if

                      carbohydrates  consumption  is  not  adequate.  So,  added
                      carbohydrates should be ingested if pre-exercise glucose levels are

                      < 100 mg/dl.

                Exercise in presence of long-term complication of diabetes:
                     Retinopathy:  in  the  presence  of  severe  proliferative  diabetic

                      retinopathy , severe or vigorous aerobic or resistance exercise may
                      be  contraindicated  because  the  risk  of  trigging  vitreous

                      hemorrhage or retinal detachment
                     Peripheral  neuropathy:  in  the  presence  of  severe  neuropathy,  it

                      may  be  best  to  encourage  non-weight-bearing  activities  such  as
                      swimming, bicycling or arm exercise.

                     Albuminuria  and  nephropathy:  physical  activity  can  acutely
                      increase urinary protein excretion. However, there is no evidence

                      that vigorous exercise increase the rate of progression of diabetic
                      kidney disease so there is no need for specific exercise restrictions

                      for people with diabetic kidney disease.
               2)  Pharmacologic management of diabetes.

                 a)  Oral hypoglycemic drugs:

               Oral  hypoglycemic  drugs  are  used  in  treating  persons  with  type  2

               diabetes who are controlled by diet and exercise.


                Groups of oral hypoglycemic drugs:



               Group                         Name                  Recommended  daily  dose
                                             Mode of action


               Insulin                       Glibenclamide     5–20mg/day             Stimulate
               secretagogues                 insulin secretion


               1.  Sulfonylurea              Glyburide           2.5–20 mg/day





                                                          240
   266   267   268   269   270   271   272   273   274   275   276